Laffin Michael, Millan Braden, Madsen Karen L
a Department of Medicine, CEGIIR: Center of Excellence for Gastrointestinal Inflammation and Immunity Research , University of Alberta , Edmonton , Alberta.
b Cumming School of Medicine , University of Calgary , Calgary , Alberta.
Gut Microbes. 2017 May 4;8(3):221-224. doi: 10.1080/19490976.2016.1278105. Epub 2017 Jan 6.
Despite increasing interest in fecal microbiota transplantation (FMT), its full therapeutic potential has yet to be determined. Since its increase in popularity, FMT has been shown to be highly effective in the treatment of both Clostridium difficile infection (CDI) and its recurrent form. Interest in FMT now expands well beyond the treatment of CDI to other processes with known associations to the microbiota such as antibiotic resistant infections, inflammatory bowel disease (IBD), hepatic encephalopathy, neuropsychiatric disorders, and metabolic disease. The rampant use and misuse of antibiotics in both medicine and agriculture has resulted in an increase in antibiotic resistant organisms which pose a significant risk to human health. The purpose of this commentary is to address the general issue of antibiotic resistance in the human microbiota and the restorative potential of FMT in this area.
尽管对粪便微生物群移植（FMT）的兴趣日益增加，但其全部治疗潜力尚未确定。自其 popularity 增加以来，FMT 已被证明在治疗艰难梭菌感染（CDI）及其复发形式方面非常有效。现在，对 FMT 的兴趣远远超出了 CDI 的治疗范围，扩展到了与微生物群有已知关联的其他病症，如抗生素耐药性感染、炎症性肠病（IBD）、肝性脑病、神经精神疾病和代谢疾病。医学和农业中抗生素的 rampant 使用和滥用导致了抗生素耐药生物的增加，这对人类健康构成了重大风险。本评论的目的是探讨人类微生物群中抗生素耐药性的一般问题以及 FMT 在该领域的恢复潜力。
